Fitness cost of drug resistance in Mycobacterium tuberculosis

Clinical Microbiology and Infection

Volumn 15, Issue SUPPL. 1, 2009, Pages 66-68

  Gagneux, S ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Antibiotic; Competition; Genotype; Mutation; Mycobacteria; Transmission

Indexed keywords

ANTIINFECTIVE AGENT; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL GENETICS; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; BACTERIUM MUTANT; COST BENEFIT ANALYSIS; HUMAN; MOLECULAR EPIDEMIOLOGY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

CORYNEBACTERINEAE; MYCOBACTERIUM TUBERCULOSIS;

EID: 59649103754     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.02685.x     Document Type: Review

References (14)

1. Palumbi SR. Humans as the world's greatest evolutionary force. Science 2001; 293: 1786-1790.
2. Raviglione MC, Smith IM. XDR tuberculosis-implications for global public health. N Engl J Med 2007; 356: 656-659.
3. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
4. Andersson DI, Levin BR. The biological cost of antibiotic resistance. Curr Opin Microbiol 1999; 2: 489-493.
5. Maisnier-Patin S, Andersson DI. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res Microbiol 2004; 155: 360-369.
6. Blower SM, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004; 10: 1111-1116.
7. Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 2004; 10: 1117-1121.
8. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312: 1944-1946.
9. Gagneux S, Burgos MV, DeRiemer K et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog 2006; 2: E61.
10. Heym B, Alzari PM, Honore N, Cole ST. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 1995; 15: 235-245.
11. Pym AS, Saint-Joanis B, Cole ST. Effect of katG Mutations on the Virulence of Mycobacterium tuberculosis and the Implication for Transmission in Humans. Infect Immun 2002; 70: 4955-4960.
12. Gagneux S, Deriemer K, Van T et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2006; 103: 2869-2873.
13. Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 2007; 7: 328-337.
14. Bifani PJ, Mathema B, Kurepina NE, Kreiswirth BN. Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol 2002; 10: 45-52.